Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2017’, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)

The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects

The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aldeyra Therapeutics Inc

Allergan Plc

Ascendia Pharmaceuticals LLC

BioLineRx Ltd

Cambium Medical Technologies LLC

Chong Kun Dang Pharmaceutical Corp

Dompe Farmaceutici SpA

Elasmogen Ltd

HanAll Biopharma Co Ltd

Herantis Pharma Plc

Huons Co Ltd

InSite Vision Inc

Kala Pharmaceuticals Inc

KPI Therapeutics Inc

Kukje Pharmaceutical Industry Co Ltd

Laboratoires Thea SA

Lipicard Technologies Ltd

Merck & Co Inc

Mimetogen Pharmaceuticals Inc

Mitotech SA

Nanomerics Ltd

Nemus Bioscience Inc

Neuroptis Biotech

Novaliq GmbH

Ocular Therapeutix Inc

Oculis ehf

OncoNOx ApS

Otsuka Holdings Co Ltd

Parion Sciences Inc

Quorum Innovations LLC

RegeneRx Biopharmaceuticals Inc

Samjin Pharmaceutical Co Ltd

Santen Pharmaceutical Co Ltd

Seikagaku Corp

Shire Plc

Sun Pharmaceutical Industries Ltd

TearSolutions LLC

TopiVert Ltd

Vanda Pharmaceuticals Inc

Xigen SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Keratoconjunctivitis sicca (Dry Eye) - Overview 8

Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Products under Development by Companies 14

Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development 28

Aldeyra Therapeutics Inc 28

Allergan Plc 28

Ascendia Pharmaceuticals LLC 29

BioLineRx Ltd 29

Cambium Medical Technologies LLC 30

Chong Kun Dang Pharmaceutical Corp 30

Dompe Farmaceutici SpA 31

Elasmogen Ltd 31

HanAll Biopharma Co Ltd 32

Herantis Pharma Plc 32

Huons Co Ltd 33

InSite Vision Inc 33

Kala Pharmaceuticals Inc 34

KPI Therapeutics Inc 34

Kukje Pharmaceutical Industry Co Ltd 35

Laboratoires Thea SA 35

Lipicard Technologies Ltd 36

Merck & Co Inc 36

Mimetogen Pharmaceuticals Inc 37

Mitotech SA 37

Nanomerics Ltd 38

Nemus Bioscience Inc 38

Neuroptis Biotech 39

Novaliq GmbH 39

Ocular Therapeutix Inc 40

Oculis ehf 40

OncoNOx ApS 41

Otsuka Holdings Co Ltd 41

Parion Sciences Inc 42

Quorum Innovations LLC 42

RegeneRx Biopharmaceuticals Inc 43

Samjin Pharmaceutical Co Ltd 43

Santen Pharmaceutical Co Ltd 44

Seikagaku Corp 44

Shire Plc 45

Sun Pharmaceutical Industries Ltd 45

TearSolutions LLC 46

TopiVert Ltd 46

Vanda Pharmaceuticals Inc 47

Xigen SA 47

Keratoconjunctivitis sicca (Dry Eye) - Drug Profiles 48

ADX-102 - Drug Profile 48

ADX-103 - Drug Profile 53

AGN-195263 - Drug Profile 54

AGN-223575 - Drug Profile 55

AGN-232411 - Drug Profile 56

AL-41A1 - Drug Profile 57

Androgen Tears - Drug Profile 58

AVA-3486 - Drug Profile 59

AVX-012 - Drug Profile 60

AX-1606 - Drug Profile 61

BL-1230 - Drug Profile 62

BRM-421 - Drug Profile 63

cenegermin - Drug Profile 64

cinhyaluronate sodium - Drug Profile 67

Cis-Urocanic Acid - Drug Profile 68

cyclosporine - Drug Profile 70

cyclosporine - Drug Profile 73

cyclosporine - Drug Profile 75

cyclosporine - Drug Profile 76

cyclosporine - Drug Profile 77

cyclosporine - Drug Profile 78

cyclosporine - Drug Profile 79

cyclosporine SR - Drug Profile 80

dexamethasone acetate SR - Drug Profile 81

diclofenac sodium - Drug Profile 87

diquafosol tetrasodium - Drug Profile 88

Drug for Dry Eye - Drug Profile 90

Drugs to Agonize FPR2 for Dry Eye - Drug Profile 91

Elate Ocular - Drug Profile 92

ELN-22 - Drug Profile 93

HL-036 - Drug Profile 94

HU-007 - Drug Profile 95

hyaluronate sodium - Drug Profile 96

ISV-101 - Drug Profile 97

K-089 - Drug Profile 98

KeraKlear - Drug Profile 99

KJ-14003 - Drug Profile 100

KJ-16001 - Drug Profile 101

KL-7016 - Drug Profile 102

KPI-190 - Drug Profile 103

Lacripep - Drug Profile 104

Leukothera - Drug Profile 105

lifitegrast - Drug Profile 107

LME-636 - Drug Profile 111

loteprednol etabonate - Drug Profile 112

LT-4002 - Drug Profile 115

LT-4003 - Drug Profile 116

NB-2222 - Drug Profile 117

NOP-3 - Drug Profile 118

NOP-5 - Drug Profile 119

Nov-03 - Drug Profile 120

OC-301 - Drug Profile 121

OTX-101 - Drug Profile 122

OX-1001 - Drug Profile 124

P-321 - Drug Profile 125

plastoquinone decyl triphenylphosphonium bromide - Drug Profile 127

PPL-003 - Drug Profile 129

Protearin - Drug Profile 131

Qi-401 - Drug Profile 132

rebamipide - Drug Profile 133

RGN-259 - Drug Profile 135

RP-101 - Drug Profile 142

SA-001 - Drug Profile 143

SJP-002 - Drug Profile 144

Small Molecule to Agonize Glucocorticoid Receptor for Dry Eye - Drug Profile 145

solithromycin - Drug Profile 146

ST-266 - Drug Profile 160

tadekinig alfa - Drug Profile 162

tavilermide hydrochloride - Drug Profile 163

TOP-1630 - Drug Profile 165

XG-104 - Drug Profile 166

zucapsaicin - Drug Profile 167

Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects 169

Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products 173

Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones 174

Featured News & Press Releases 174

Appendix 181

Methodology 181

Coverage 181

Secondary Research 181

Primary Research 181

Expert Panel Validation 181

Contact Us 181

Disclaimer 182

List of Tables

List of Tables

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Aldeyra Therapeutics Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Allergan Plc, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Ascendia Pharmaceuticals LLC, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by BioLineRx Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Cambium Medical Technologies LLC, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Dompe Farmaceutici SpA, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Elasmogen Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by HanAll Biopharma Co Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Herantis Pharma Plc, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Huons Co Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by InSite Vision Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Kala Pharmaceuticals Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by KPI Therapeutics Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Kukje Pharmaceutical Industry Co Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Laboratoires Thea SA, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Lipicard Technologies Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Merck & Co Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Mimetogen Pharmaceuticals Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Mitotech SA, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Nanomerics Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Nemus Bioscience Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Neuroptis Biotech, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Novaliq GmbH, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Ocular Therapeutix Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Oculis ehf, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by OncoNOx ApS, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Otsuka Holdings Co Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Parion Sciences Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Quorum Innovations LLC, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Santen Pharmaceutical Co Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Seikagaku Corp, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Shire Plc, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Sun Pharmaceutical Industries Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by TearSolutions LLC, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by TopiVert Ltd, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Vanda Pharmaceuticals Inc, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Xigen SA, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Dormant Projects, H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Dormant Projects, H1 2017 (Contd..2), H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Dormant Projects, H1 2017 (Contd..3), H1 2017

Keratoconjunctivitis sicca (Dry Eye) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports